Nuo Therapeutics Reports Q3 Revenue Growth to $1.9 Million with Minimal GAAP EPS Loss
Nuo Therapeutics (AURX) has released its third-quarter financial results, reporting a significant year-over-year revenue increase of 84.5%, reaching $1.9 million. Despite the substantial top-line growth, the company reported a narrow GAAP earnings per share (EPS) loss of $0.01. The results highlight strong momentum in revenue generation compared to the previous year. While the company remains in a net loss position, the minimal EPS deficit suggests an improving trajectory in managing operational costs relative to its expanding revenue base.

Tickers: $AURX
Topics: earnings GAAP EPS revenue growth